Diversity in Clinical Pharmacology: A Call to Action

被引：4

作者：

Brown, Karen ^{[1
]}

Etrouth, Shravani ^{[2
]}

Jayachandran, Priya ^{[3
]}

Moore, Jason ^{[4
]}

Oni-Orisan, Akinyemi ^{[5
]}

Vasist, Lakshmi ^{[6
]}

Zheng, Songmao ^{[7
]}

Zhou, Zhu ^{[8
]}

Dresser, Mark ^{[5
,9
]}

机构：

[1] Univ Montana, Missoula, MT USA

[2] Jawaharlal Nehru Technol Univ, Hyderabad, India

[3] Pfizer Inc, Cambridge, MA USA

[4] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol, Silver Spring, MD USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] GlaxoSmithKline, Chapel Hill, NC USA

[7] Adagene Inc, San Diego, CA USA

[8] CUNY York Coll, Jamaica, NY USA

[9] Gilead Sci Inc, Foster City, CA 94404 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷 / 03期

关键词：

D O I：

10.1002/cpt.2852

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Prioritization of diversity, equity, and inclusion in all facets of our work is long overdue for the clinical pharmacology community. Increasing diversity in clinical research will deepen our understanding of nuanced patient populations and help improve all patient outcomes. Fostering an inclusive and diverse workforce will lead to broader perspectives that can better inform critical decisions and create work environments where everyone can thrive. In this call to action, we invite you to join us.

引用

页码：483 / 485

页数：3

共 10 条

[1]

[Anonymous], The U.S. Public Health Service Syphilis Study at Tuskegee

[2]

[Anonymous], 2021, 2020 DRUG TRIALS SNA

[3]

Bommersbach J., 2008, PHOENIX MAGAZINE, V134

[4] Imposter syndrome threatens diversity [J].